Drugs / CD19/BCMA CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05085431 | Nov 2021 → Nov 2024 | Sjogren syndrome | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05085431 ↗ |
| Action | Deplete | “This research focuses on CAR-T cells killing B cells.” NCT05085431 ↗ |
| Modality | Cell therapy | “This research focuses on CAR-T cells killing B cells.” NCT05085431 ↗ |
| Target | CD19 | “CD19/BCMA CAR T-cells” NCT05085431 ↗ |